Effect of Cerebral Microbleeds on Cognitive Function and Quality of Life in Parkinson Disease

16 March 2022: Clinical Research

Qixiong Qin ^1ABCDEF , Hengming Wan ^2C , Danlei Wang ^1B , Jingyi Li ^1B , Qingmei Yang ^1B , Jingwei Zhao ^1B , Zheng Xue ^1ADFG

DOI: 10.12659/MSM.935026

Med Sci Monit 2022; 28:e935026

Table 3 Quality of life assessment in patients with different locations of cerebral microbleeds.

	CMBs free (n=162)	Lobar CMBs (n=15)	Deep CMBs (n=17)	Mixed CMBs (n=10)	p-value
PDQ-39 SI	24.83±13.55	30.94±15.46	28.51±14.14	39.36±12.40^#	0.012
Mobility SI	29.52±23.55	44.33±29	34.56±26.53	47.75±23.44	0.035
Activity of daily living SI	28.02±20.39	38.89±29.99	30.39±23.23	50.41±21.73^#	0.023
Emotional well-beings SI	27.48±18.26	31.67±17.27	28.68±19.40	26.25±17.63	0.860
Stigma SI	24.32±23.14	25.00±31.16	25.74±26.13	37.38±16.80	0.228
Social support SI	8.17±17.13	7.78±14.92	8.82±16.53	10.83±20.05	0.984
Cognitions SI	27.88±19.81	29.17±19.42	35.05±20.52	41.70±19.43	0.037
Communication SI	16.08±20.18	24.99±24.19	17.16±26.76	26.67±21.44	0.189
Bodily discomfort SI	19.23±20.18	15.55±15.06	25.98±16.89	20.00±18.09	0.248
Data are presented as means±standard deviation. The comparison among groups was performed using Kruskal-Wallis test, and Bonferroni corrections were used for multiple comparisons. ^# Compared with CMB-free group, the difference was statistically significant. CMBs – cerebral microbleeds; PDQ – 39-item Parkinson’s disease questionnaire; SI – summary index.